Liquid Biopsy in Cancer Diagnostics Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)

Publication ⇒Dec-23 Delivery Time ⇒ 5-7 Business Days Report Code ⇒PBCHC275-10M-OT

License Type (Price in USD)

Liquid Biopsy in Cancer Diagnostics Market – Report Overview

Pacific Business Consulting’s “Liquid Biopsy in Cancer Diagnostics Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of Liquid Biopsy in Cancer Diagnostics market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.

The global Liquid Biopsy in Cancer Diagnostics market, valued at US$ 8.0 Billion in 2022, is projected to grow at a Compound Annual Growth Rate (CAGR) of more than 15.0% from 2023 to 2030, reaching a value of more than US$ 20.0 Billion by 2030.

Liquid biopsy has emerged as a convenient, fast, non-invasive, and reproducible sampling method for cancer diagnostics. It reflects changes in the tumor gene expression profile and provides a robust foundation for individualized therapy and early cancer diagnosis. Liquid biopsy has gained widespread attention as a non-invasive alternative to tissue biopsy, focusing on screening early cancer, monitoring tumor progression, assessing therapeutic response and clinical prognosis, and detecting recurrent and refractory tumors.

The World Health Organization (WHO) reported around 10 million cancer-related deaths in 2020, emphasizing the demand for convenient and precise cancer diagnostic tests for early detection. Governments of different economies are providing funds for improved cancer outcomes, with the National Cancer Institute in the United States, for example, receiving US$ 119 million in 2021.

Researchers continue to advance biomarkers for cancer detection and evaluation using liquid biopsy. The development of new biomarkers for early cancer detection and treatment response is a key aspect contributing to the growth of liquid biopsy in cancer diagnostics.

The increasing prominence of precision medicine in cancer care is another significant driver of the demand for liquid biopsy. Precision medicine involves individualizing treatment plans based on the biological behavior of the tumor. Liquid biopsy plays a crucial role in providing real-time information about the tumor profile, aiding in customized treatment decisions. Market players are recognizing the potential of liquid biopsy, as evident from their interest in product development in this domain.

Advancements such as next-generation sequencing for advanced cancer patients in liquid biopsies, the rise in the number of cancer patients, and patient preference for minimally invasive therapies contribute to the growth of the liquid biopsy market. However, lack of awareness in developing regions is a limiting factor. The increase in healthcare expenditure in developing countries and the use of liquid biopsy tests to treat rare cancers present opportunities for market growth.

Key players in the Liquid Biopsy in Cancer Diagnostics segment, including Illumina Inc, QIAGEN, Lucence Health Inc, Personal Genome Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc., Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, and Sysmex Corporation, are expected to shape the future landscape of Liquid Biopsy in Cancer Diagnostics technologies through ongoing innovation.

 

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Liquid Biopsy in Cancer Diagnostics market. It also delves into the analysis of present and prospective market competition within the global Liquid Biopsy in Cancer Diagnostics market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

  • Develop your business strategies by gaining insights into the trends that shape and drive the Liquid Biopsy in Cancer Diagnostics market across the 10MM (Ten Major Markets).
  • Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM Liquid Biopsy in Cancer Diagnostics market.
  • Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
  • Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.
  1. Executive Summary: Liquid Biopsy in Cancer Diagnostics
    • Global Market Outlook: Liquid Biopsy in Cancer Diagnostics
  2. Competitive Intelligence Analysis: Liquid Biopsy in Cancer Diagnostics
  3. Therapeutic Sector SWOT
  4. Technology Roadmap Analysis: Liquid Biopsy in Cancer Diagnostics
  5. Market Background
    • Drivers
    • Restraints
    • Opportunity
    • Key Market Trends
    • Key Unmet Needs
  6. Key Marketed Products Profile – Major Approved Products: Liquid Biopsy in Cancer Diagnostics
    • Product Profile
    • Safety and Efficacy
  7. Regulatory Landscape
  8. Liquid Biopsy in Cancer Diagnostics: Ten Major Market (10MM) – Market Analysis, By Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Lung Cancer
    • Others
  9. Liquid Biopsy in Cancer Diagnostics: Ten Major Market (10MM) – Market Analysis, By Biomarker Type
    • Circulating Tumor Cells (CTCs)
    • Circulating Tumor DNA (ctDNA)
    • Circulating Free DNA (cfDNA)
    • Others
  10. Liquid Biopsy in Cancer Diagnostics: Ten Major Market (10MM) – Market Analysis, By End User
    • Hospitals
    • Diagnostic Centers
    • Academic & Research Organizations
    • Others
  11. Liquid Biopsy in Cancer Diagnostics: Ten Major Market (10MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. S. Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. K. Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. Germany Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. France Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. Italy Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. Spain Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. Japan Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. China Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. Australia Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. India Liquid Biopsy in Cancer Diagnostics – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
      • By Cancer Type
      • By Biomarker Type
      • By End User
    • Current and Future Market Projections (US$ million), 2023-2030
      • By Cancer Type
      • By Biomarker Type
      • By End User
  1. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

  1. Assumptions and Acronyms Used
  2. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
  3. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, China, Australia, and India
  4. Copyrights and Disclaimer

Customize Reports As Per Your Needs

Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!

Have A Question?

We are happy to assist you.

Phone:+919599779105
Email:info@pacificbusinessconsulting.com